Related Experiment Video
Updated: Dec 11, 2025

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Increased miR-7641 Levels in Peritoneal Hyalinizing Vasculopathy in Long-Term Peritoneal Dialysis Patients
Raquel Díaz1,2, Pilar Sandoval3, Raul R Rodrigues-Diez2,4
1Research Institute of La Paz (IdiPAZ), University Hospital La Paz, 28046 Madrid, Spain.
Insights
Peritoneal hyalinizing vasculopathy (PHV) in peritoneal dialysis (PD) patients may stem from endothelial-to-mesenchymal transition (EndMT) driven by glucose degradation products (GDPs). Lower PHV rates were observed with protective factors like ACE inhibitors and statins.
Area of Science:
- Nephrology
- Vascular Biology
- Molecular Biology
Background:
- Peritoneal hyalinizing vasculopathy (PHV) is a key feature of encapsulating peritoneal sclerosis in long-term peritoneal dialysis (PD) patients.
- The underlying mechanisms driving PHV development are not well understood.
Purpose of the Study:
- To investigate the pathological mechanisms of PHV in PD patients.
- To identify potential protective factors against PHV development.
Main Methods:
- Cross-sectional study of 100 PD patient peritoneal biopsies.
- Clinical data collection and immunohistochemical evaluation of lesions.
- MicroRNA (miRNA)-sequencing analysis in selected biopsies.
Main Results:
- PHV was present in 15% of patients, with lower prevalence linked to low glucose degradation products (GDPs), ACE inhibitors, statins, and residual renal function.
- PHV biopsies showed endothelial marker loss, mesenchymal protein induction, collagen IV accumulation, and basement membrane reduplication.
- Evidence of endothelial-to-mesenchymal transition (EndMT) and activated TGF-β1/Smad3 signaling was observed.
- Higher miR-7641 levels were found in severe PHV cases.
Conclusions:
- Glucose degradation products (GDPs) may induce miRNA deregulation and EndMT in peritoneal submesothelial vessels, contributing to PHV.
- ACE inhibitors, statins, and residual renal function may offer protection against PHV.
Abstract:
Peritoneal hyalinizing vasculopathy (PHV) represents the cornerstone of long-term peritoneal dialysis (PD), and especially characterizes patients associated with encapsulating peritoneal sclerosis. However, the mechanisms of PHV development remain unknown. A cross sectional study was performed in 100 non-selected peritoneal biopsies of PD patients. Clinical data were collected and lesions were evaluated by immunohistochemistry. In selected biopsies a microRNA (miRNA)-sequencing analysis was performed. Only fifteen patients (15%) showed PHV at different degrees. PHV prevalence was significantly lower among patients using PD fluids containing low glucose degradation products (GDP) (5.9% vs. 24.5%), angiotensin converting enzyme inhibitors (ACEIs) (7.5% vs. 23.4%), statins (6.5% vs. 22.6%) or presenting residual renal function, suggesting the existence of several PHV protective factors. Peritoneal biopsies from PHV samples showed loss of endothelial markers and induction of mesenchymal proteins, associated with collagen IV accumulation and wide reduplication of the basement membrane. Moreover, co-expression of endothelial and mesenchymal markers, as well as TGF-β1/Smad3 signaling activation were found in PHV biopsies. These findings suggest that an endothelial-to-mesenchymal transition (EndMT) process was taking place. Additionally, significantly higher levels of miR-7641 were observed in severe PHV compared to non-PHV peritoneal biopsies. Peritoneal damage by GDPs induce miRNA deregulation and an EndMT process in submesothelial vessels, which could contribute to collagen IV accumulation and PHV.
Related Concept Videos
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Peritoneal Dialysis III: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Peritoneal Dialysis I: Introduction and Procedure

